Skip to main content
. Author manuscript; available in PMC: 2020 Aug 19.
Published in final edited form as: Nature. 2020 Feb 19;579(7797):130–135. doi: 10.1038/s41586-020-2015-4

Figure 1: IL33-dependent ILC2s infiltrate human and murine pancreatic cancer.

Figure 1:

(a) Gating, frequency, and phenotype of ILCs in unselected human PDAC patients. (b) Frequency (top) and survival association (bottom) of ILC2s in tumor tissue microarrays of short-term and long-term PDAC survivors. (c) Bulk tumor IL33 mRNA associations with survival and correlation with tumor cytolytic index (CYT) in short- and long-term PDAC survivors. (d) Gating and frequency of ILCs in PDAC mice. (e) Intratumoral ILC frequency and number in Rag2−/− PDAC mice treated with αCD90.2 or isotype (Iso) antibodies. (f) Gating, frequency, and number of ILCs in Il33+/+ and Il33−/− PDAC mice. High and low in b, c defined as higher or lower, respectively, than the median for the cohort. Data were collected at 14 (d-f) post tumor implantation. n, number of tumors from individual patients or mice. Horizontal bars mark medians. Data in d-f are pooled from ≥2 independent experiments with n≥3/group; each point indicates one mouse analyzed separately. P values determined by one-way ANOVA with Tukey’s (a) and Kruskal-Wallis multiple comparison post-tests (d), two-tailed Mann-Whitney test (b, e, f), two-sided log-rank (b, c survival curves), and linear regression (c).